Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

New cancer drugs linked to fewer arrhythmias

Nickel A et al. annual meeting of the American College of Cardiology ACC 18, Abstract #900-06.

Key clinical point: The novel targeted cancer therapies cause markedly fewer cardiac arrhythmias.

Major finding: Cancer patients treated with a tyrosine kinase inhibitor, immune checkpoint inhibitor, or another of the novel targeted therapies were 40% less likely than were those on anthracycline-based therapy to develop a treatment-induced cardiac arrhythmia up to 6 months after treatment initiation.

Study details: This was a retrospective single-center study including more than 5,000 cancer patients.

Disclosures: The presenter reported having no financial conflicts regarding his study, which was conducted free of commercial support.

Source: Nickel A et al. ACC 18, Abstract #900-06.

Read the article.

Citation:

Nickel A et al. annual meeting of the American College of Cardiology ACC 18, Abstract #900-06.

This Week's Must Reads

Gene sequencing sheds light on outcomes in MPN, Grinfeld J et al. N Engl J Med. 2018;379:1416-30

Phase 2 trial evaluates entospletinib in DLBCL, Burke JM et al. Clin Lymphoma Myeloma Leuk. 2018 Aug;18(8):e327-e331

Obesity lowers risk of death in PE patients, Khan Z et al. CHEST. 2018 Oct. doi: 10.1016/j.chest.2018.08.919

T cell infusion effective in PML, Muftuoglu M et al. N Engl J Med. 2018 Oct 11;379:1443-51

Must Reads in Thrombosis

Gene sequencing sheds light on outcomes in MPN, Grinfeld J et al. N Engl J Med. 2018;379:1416-30

Obesity lowers risk of death in PE patients, Khan Z et al. CHEST. 2018 Oct. doi: 10.1016/j.chest.2018.08.919

Throly system predicts thromboprophylaxis in lymphoma patients, Leukemia and Lymphoma 2018, Dubrovnik, Croatia

VTE risk for continuous cycle oral contraceptives, Li J et al. JAMA Intern Med. 2018 Oct 1. doi:10.1001/jamainternmed.2018.4251